CPRX - Catalyst Pharmaceuticals, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Coral Gables,
United States
Type: Equity
CPRX price evolution
CPRX
| (in millions $) | 30 Jul 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $375.69 | $310.41 | $137.64 | $120.97 |
| Short term investments | ||||
| Net receivables | $57.17 | $60.49 | $53.51 | $48.05 |
| Inventory | $18.01 | $19.95 | $15.64 | $9.04 |
| Total current assets | $474.43 | $404.6 | $219.33 | $192.02 |
| Long term investments | $13.08 | $15.35 | $16.49 | $12.9 |
| Property, plant & equipment | $3.6 | $3.75 | $3.7 | $3.76 |
| Goodwill & intangible assets | $175.36 | $184.71 | $194.05 | $167.11 |
| Total noncurrent assets | $231.93 | $242.07 | $250.78 | $221.19 |
| Total investments | $13.08 | $15.35 | $16.49 | $12.9 |
| Total assets | $706.36 | $646.68 | $470.11 | $413.21 |
| Current liabilities | ||||
| Accounts payable | $7.12 | $10.26 | $14.79 | $4.6 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $92.32 | $79.57 | $76.06 | $57.81 |
| Long term debt | $2.99 | $3.09 | $3.19 | $3.28 |
| Total noncurrent liabilities | $5.39 | $5.7 | $6.17 | $6.86 |
| Total debt | $2.99 | $3.09 | $3.19 | $3.28 |
| Total liabilities | $97.7 | $85.26 | $82.23 | $64.66 |
| Shareholders' equity | ||||
| Retained earnings | $185.34 | $144.55 | $121.27 | $86.43 |
| Other shareholder equity | $0.01 | $0.01 | ||
| Total shareholder equity | $608.65 | $561.41 | $387.88 | $348.55 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $137.64 | $298.4 | $171.45 | $130.25 |
| Short term investments | $19.82 | $10.04 | ||
| Net receivables | $53.51 | $10.44 | $6.62 | $5.99 |
| Inventory | $15.64 | $6.8 | $7.87 | $4.65 |
| Total current assets | $219.33 | $320.8 | $210.11 | $159.24 |
| Long term investments | $16.49 | |||
| Property, plant & equipment | $3.7 | $3.62 | $3.98 | $0.13 |
| Goodwill & intangible assets | $194.05 | $32.47 | ||
| Total noncurrent assets | $250.78 | $54.83 | $27.68 | $33.11 |
| Total investments | $16.49 | $19.82 | $10.04 | |
| Total assets | $470.11 | $375.63 | $237.79 | $192.35 |
| Current liabilities | ||||
| Accounts payable | $14.79 | $3.98 | $2.77 | $4.26 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $76.06 | $57.59 | $27.06 | $22.76 |
| Long term debt | $3.19 | $3.56 | $3.89 | |
| Total noncurrent liabilities | $6.17 | $17.62 | $3.89 | |
| Total debt | $3.19 | $3.56 | $3.89 | |
| Total liabilities | $82.23 | $75.21 | $30.96 | $22.76 |
| Shareholders' equity | ||||
| Retained earnings | $121.27 | $49.86 | -$26.31 | -$53.71 |
| Other shareholder equity | $0.01 | $0.02 | -$0.15 | $0.03 |
| Total shareholder equity | $387.88 | $300.42 | $206.83 | $169.6 |
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $98.51 | $110.57 | ||
| Cost of revenue | $12.52 | $15.81 | ||
| Gross Profit | $85.99 | $94.76 | ||
| Operating activities | ||||
| Research & development | $2.58 | $1.97 | ||
| Selling, general & administrative | $46.94 | $42.04 | ||
| Total operating expenses | $58.86 | $53.07 | ||
| Operating income | $27.13 | $41.69 | ||
| Income from continuing operations | ||||
| EBIT | $29.09 | $46.71 | ||
| Income tax expense | $5.81 | $11.86 | ||
| Interest expense | ||||
| Net income | ||||
| Net income | $23.27 | $34.84 | ||
| Income (for common shares) | $23.27 | $34.84 | ||
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $398.2 | $214.2 | $140.83 | $119.07 |
| Cost of revenue | $51.97 | $34.39 | $21.88 | $17.04 |
| Gross Profit | $346.24 | $179.81 | $118.95 | $102.03 |
| Operating activities | ||||
| Research & development | $93.15 | $19.79 | $16.94 | $16.5 |
| Selling, general & administrative | $133.71 | $58.18 | $49.63 | $44.23 |
| Total operating expenses | $259.43 | $77.97 | $66.56 | $60.73 |
| Operating income | $86.81 | $101.84 | $52.38 | $41.3 |
| Income from continuing operations | ||||
| EBIT | $94.51 | $104.72 | $52.67 | $41.89 |
| Income tax expense | $23.1 | $21.64 | $13.19 | -$33.09 |
| Interest expense | ||||
| Net income | ||||
| Net income | $71.41 | $83.08 | $39.48 | $74.98 |
| Income (for common shares) | $71.41 | $83.08 | $39.48 | $74.98 |
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Net income | $40.79 | $23.27 | $34.84 | -$30.76 |
| Operating activities | ||||
| Depreciation | $9.5 | $9.5 | $9.21 | $8.63 |
| Business acquisitions & disposals | -$36 | |||
| Stock-based compensation | $4.41 | $8.25 | $4.25 | $3.81 |
| Total cash flows from operations | $64.14 | $31.93 | $55.65 | $45.13 |
| Investing activities | ||||
| Capital expenditures | -$0.01 | -$0.2 | -$0.09 | -$0.06 |
| Investments | -$13.46 | |||
| Total cash flows from investing | -$0.01 | -$0.2 | -$38.32 | -$92.82 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $2.03 | $142.23 | $0.69 | $0.21 |
| Net borrowings | ||||
| Total cash flows from financing | $1.16 | $141.05 | -$0.67 | -$10.13 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $65.28 | $172.78 | $16.66 | -$57.82 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $71.41 | $83.08 | $39.48 | $74.98 |
| Operating activities | ||||
| Depreciation | $33.14 | $1.49 | $0.48 | $0.89 |
| Business acquisitions & disposals | -$198.29 | -$10 | ||
| Stock-based compensation | $14.25 | $7.91 | $6.07 | $6.26 |
| Total cash flows from operations | $143.6 | $116.05 | $60.37 | $45.03 |
| Investing activities | ||||
| Capital expenditures | -$0.23 | -$0.03 | -$1.02 | -$0.01 |
| Investments | -$13.46 | $19.24 | -$10 | -$5 |
| Total cash flows from investing | -$293.5 | $9.21 | -$11.02 | -$5.01 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $2.79 | $2.66 | -$7.99 | $0.76 |
| Net borrowings | ||||
| Total cash flows from financing | -$10.86 | $1.69 | -$8.14 | $0.7 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$160.76 | $126.95 | $41.21 | $40.73 |
News
Fundamentals
| Market cap | $2.52B |
|---|---|
| Enterprise value | $2.15B |
| Shares outstanding | 118.52M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 4.14 |
| Book/Share | 5.14 |
| Cash/Share | 3.17 |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.21 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 5.14 |
| Quick ratio | 4.94 |